Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study

Causse, Xavier; Payen, Jean‐Louis; Izopet, Jacques; Babany, G; Girardin, Marie-France Saint-Marc; Bailly, François; Housset, Chantal; Tran, Albert; Pariente, Alexandre; Jp, Lagasse; Desmorat, Hervé; Bettan, Louis; Bloch, Francis; Couzigou, Patrice; Chossegros, P.; Laurent, Puig P; Bacq, Yannick; Douvin, Catherine; Raabe, J.-J.; Lemmens, C Van; Zarski, J.-R.; Bernard, Pierre; Rozenbaum, Willy; Vallets, D Trois; Fischer, D; Sogni, Philippe; Boucher, Éveline; Boyer, Nathalie; Jm, Lang; Danne, O; Jc, Barbare; Force, Gilles; Schmit, JL; Mesnard, B; Gauthier, A.; Jd, Poveda; Sayada, Chalom; Olivares, Robert; Montestruc, François

doi:10.1016/s0168-8278(00)80105-1

Cited by 38 publications

(16 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, a similar treatment regimen was associated with a 40% sustained response rate among HIV-infected patients from the same hemophilia unit. This figure is 2-to 3-fold higher than those obtained in HIV-infected nonhemophiliac patients given interferon monotherapy 14,15 and similar to those reported among HIV-HCV-coinfected drug users given interferon and ribavirin combination therapy for 6 to 12 months. [23][24][25][26] As in immunocompetent patients, there was a tendency towards a higher sustained response rate among patients with genotype 2 or 3 (80%) as compared with those with genotype 1 or 4 (27%).…”

Section: Discussionsupporting

confidence: 82%

“…In the two largest such studies, conducted before HAART became available, sustained response rates similar to those observed in HIV-negative patients were reported, at least in patients with conserved CD4 cell count. 14,15 Although at present it is widely accepted that HIV-HCVcoinfected patients should be considered for interferon treatment, concerns regarding tolerance in patients already receiving multiple drugs and fears of pharmacologic interference with antiretroviral medication have prevented widespread treatment of hepatitis C in these patients. 16,17 Because of the increasing need for efficient therapeutic regimens to treat HCV infection in HIV-infected hemophiliacs and the promising results of combination therapy in HIVnegative patients, 18,19 we conducted an open trial involving 20 HIV-HCV-coinfected patients with congenital clotting disorders, to assess the tolerance to and efficacy of a 6-to 12-month course of interferon and ribavirin combination.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus–infected patients with congenital coagulation disorders

Sauleda

2001

Hepatology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 82%

mentioning

confidence: 99%

Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus–infected patients with congenital coagulation disorders

Sauleda

2001

Hepatology

View full text Add to dashboard Cite

“…However, IFN attenuates the CD4 + cell response to HIV when it is combined with nucleoside analogues [58]. Investigators in a French prospective study reported that the response to IFN in chronic HCV infection was not statistically different in HCV-monoinfected individuals, compared with HIV-HCV coinfected individuals [59].…”

Section: Therapeutic Optionsmentioning

confidence: 99%

The HCV and HIV coinfected patient: What have we learned about pathophysiology?

Talal

Canchis

Jacobson

2002

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is an important problem in individuals who are also infected with HIV. HCV infection is very common in HIV-infected individuals, occurring in approximately one quarter to one third of this group, presumably as a consequence of shared routes of transmission related to virologic and pathogenic aspects of the viral infections. Although both are single-stranded RNA viruses and share similar epidemiologic properties, there are many important differences. Although the quantity of HIV RNA in plasma is an important prognostic determinant of HIV infection, this has not been shown with HCV. A direct relationship is apparent between HIV-related destruction of CD4 cells and the clinical consequences of the disease resulting from immunodeficiency. The pathogenesis of HCV, which occurs as a consequence of hepatic fibrosis, is much more complex. The hepatic stellate cell, the major producer of the extracellular matrix protein, is the main contributor to hepatic fibrosis, but the mechanism by which HCV induces hepatic fibrosis remains unclear. Treatment of HCV is increasingly important in HIV-infected patients due to improved HIV-associated morbidity and mortality and due to the frequency with which HCV occurs in patients with HIV-HCV coinfection. Timing of treatment initiation, management of side effects, and possible effects of anti-HCV therapy on HIV are among the issues that need consideration. Also, because several issues concerning HCV are unique to coinfected patients, further research is needed to determine optimal management of HCV in this setting.

show abstract

“…Daher ist eine Indikation zur Behandlung der Hepatitis C bei diesen Patienten gegeben. Eine Behandlung mit Interferon-α Monotherapie hat vergleichbare Ansprechraten mit HIV-negativen Patienten gezeigt [34]. Erste Daten zur Kombinationstherapie von IFN-α + Ribavirin zeigen, dass diese Behandlung auch bei HIV-Patienten sicher und effektiv zu sein scheint [35] (siehe auch Beitrag von J. Rockstroh in diesem Heft).…”

Section: Patienten Mit Hiv-koinfektionunclassified